In recent years, a new hope has risen with the new class of antidiabetic agents such as SGLT-2 inhibitors and GLP-1 receptor agonists to decrease mortality in patients with T2DM without increasing the risk of hypoglycemia. Here, GLP1R is linked to Hypoglycemia.